SUPPORT HOTLINE (888) 901-2226
Donate Now
Title
GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
NCT ID: NCT03693612
State: Multi-State Trial Investigator/Sponsoring Organization: GlaxoSmithKline
Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With Intravesical BCG in Participants W...
NCT ID: NCT03519256
State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb
STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WIT...
NCT ID: NCT03317496
State: Multi-State Trial Investigator/Sponsoring Organization: Pfizer
Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations
NCT ID: NCT02052778
State: Multi-State Trial Investigator/Sponsoring Organization: Taiho Oncology, Inc.
Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Bladder Cancer
NCT ID: NCT03207867
State: Multi-State Trial Investigator/Sponsoring Organization: Novartis Pharmaceuticals
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/o...
NCT ID: NCT03517956
State: Multi-State Trial Investigator/Sponsoring Organization: Bayer
Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15...
NCT ID: NCT04068896
State: Multi-State Trial Investigator/Sponsoring Organization: NGM Biopharmaceuticals, Inc
Study of 18Fluorine-Fluciclovine Positron Emission Tomography/Computed Tomography for Staging Muscle...
NCT ID: NCT04018053
State: Massachusetts Investigator/Sponsoring Organization: Dana-Farber Cancer Institute
Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer (NMIBC)
NCT ID: NCT03854721
State: Multi-State Trial Investigator/Sponsoring Organization: Vaxiion Therapeutics
Study of Celecoxib Combined With Gemcitabine and Cisplatin for Neoadjuvant Treatment of Localized, M...
NCT ID: NCT02885974
State: Multi-State Trial Investigator/Sponsoring Organization: Baylor College of Medicine
Study of Durvalumab (MEDI4736) Alone or in Combination With Oleclumab (MEDI9447) as Neoadjuvant Ther...
NCT ID: NCT03773666
State: Multi-State Trial Investigator/Sponsoring Organization: Dana-Farber Cancer Institute
Study of MK-3475 in Combination With BCG for Patients With High Risk Superficial Bladder Cancer
NCT ID: NCT02324582
State: Multi-State Trial Investigator/Sponsoring Organization: Southern Illinois University
Neoadjuvant Intravesical NIS Measles Virus (MV-NIS) in Patients Undergoing Cystectomy for Urothelial...
NCT ID: NCT03171493
State: Minnesota Investigator/Sponsoring Organization: Vyriad, Inc.
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasiv...
NCT ID: NCT03532451
State: Multi-State Trial Investigator/Sponsoring Organization: PrECOG, LLC.
Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinom...
NCT ID: NCT03404791
State: Multi-State Trial Investigator/Sponsoring Organization: Taris Biomedical LLC
FAST: Feasibility Trial of Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Ur...
NCT ID: NCT03287050
State: Michigan Investigator/Sponsoring Organization: University of Michigan Rogel Cancer Center
An Open-label, Phase 1 Study of KHK2455 in Combination With Avelumab in Adult Subjects With Locally ...
NCT ID: NCT03915405
State: Multi-State Trial Investigator/Sponsoring Organization: Kyowa Kirin Pharmaceutical Development, Inc.
Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin-ineligible...
NCT ID: NCT03924895
State: Multi-State Trial Investigator/Sponsoring Organization: Merck Sharp & Dohme Corp.
Study of the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Gu...
NCT ID: NCT03711032
State: Multi-State Trial Investigator/Sponsoring Organization: Merck Sharp & Dohme Corp.
Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperat...
NCT ID: NCT03924856
State: Multi-State Trial Investigator/Sponsoring Organization: Merck Sharp & Dohme Corp.
Study of Intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in Subjects With High Risk and BCG-...
NCT ID: NCT02808143
State: Illinois Investigator/Sponsoring Organization: Northwestern University
Study of TAR-200 in Combination With Nivolumab (OPDIVO) in Subjects With Muscle-Invasive Urothelial ...
NCT ID: NCT03518320
State: Multi-State Trial Investigator/Sponsoring Organization: Taris Biomedical LLC
Study of the Combination of Durvalumab (MEDI4736) and Vicinium (Oportuzumab Monatox, VB4-845) in Sub...
NCT ID: NCT03258593
State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI)
Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanc...
NCT ID: NCT03244384
State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI)
Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma...
NCT ID: NCT03837821
State: New York Investigator/Sponsoring Organization: Weill Medical College of Cornell University
Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER - (ADAPT-BLADDER) HCRN GU1...
NCT ID: NCT03317158
State: Multi-State Trial Investigator/Sponsoring Organization: Noah Hahn, M.D.
Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin f...
NCT ID: NCT03732677
State: Multi-State Trial Investigator/Sponsoring Organization: AstraZeneca
Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Be...
NCT ID: NCT03091660
State: Multi-State Trial Investigator/Sponsoring Organization: Southwest Oncology Group
Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Blad...
NCT ID: NCT03775265
State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI)
Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followe...
NCT ID: NCT02608125
State: Multi-State Trial Investigator/Sponsoring Organization: Principia Biopharma Inc.
Study of Gemcitabine and Cisplatin With Atezolizumab (MPDL3280A) in Patients With Metastatic and Mus...
NCT ID: NCT02989584
State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center
Study of WST11 Phototherapy for Upper Tract Urothelial Carcinoma
NCT ID: NCT03617003
State: New York Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center
Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab as First-line Treatment in Cispla...
NCT ID: NCT03473756
State: Multi-State Trial Investigator/Sponsoring Organization: Bayer
IV Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients: A Forgotten Group
NCT ID: NCT04046094
State: Multi-State Trial Investigator/Sponsoring Organization: University of Kansas Medical Center
Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab ...
NCT ID: NCT03661320
State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb
Study of Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Ca...
NCT ID: NCT03892642
State: Oklahoma Investigator/Sponsoring Organization: University of Oklahoma
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With ...
NCT ID: NCT02138734
State: Multi-State Trial Investigator/Sponsoring Organization: Altor BioScience
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in P...
NCT ID: NCT03869190
State: Multi-State Trial Investigator/Sponsoring Organization: Hoffmann-La Roche
Avelumab in Non-metastatic Muscle Invasive Bladder Cancer (BL-AIR: Bladder Cancer-Avelumab for Invas...
NCT ID: NCT03498196
State: Multi-State Trial Investigator/Sponsoring Organization: Baylor College of Medicine
Study of Albumin-bound Rapamycin Nanoparticles (Nab-rapamycin, ABI-009) in the Treatment of BCG Refr...
NCT ID: NCT02009332
State: Multi-State Trial Investigator/Sponsoring Organization: Aadi, LLC
Study of Daratumumab (CD38 Antagonist) in Patients With Metastatic Renal Cell Carcinoma or Muscle In...
NCT ID: NCT03473730
State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center
Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect (RITE) Wi...
NCT ID: NCT03335059
State: Multi-State Trial Investigator/Sponsoring Organization: Medical Enterprises Ltd.
Combination of Avelumab and Taxane Based Chemotherapy in Platinum Refractory or Ineligible Metastati...
NCT ID: NCT03575013
State: Iowa Investigator/Sponsoring Organization: Rohan Garje
Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma
NCT ID: NCT03854474
State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI)
Targeting a Genomic Biomarker for PET Imaging and Staging of Urothelial Cancer: A Preliminary Evalua...
NCT ID: NCT03039413
State: Pennsylvania Investigator/Sponsoring Organization: Sidney Kimmel Cancer Center at Thomas Jefferson University
Trial Evaluating the Safety and Tolerability of NanoDoce® Injection and Intravesical Instillation in...
NCT ID: NCT03636256
State: Multi-State Trial Investigator/Sponsoring Organization: NanOlogy, LLC
Tranexamic Acid During Cystectomy Trial (TACT)
NCT ID: NCT01869413
State: Multi-State Trial Investigator/Sponsoring Organization: Ottawa Hospital Research Institute
Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Canc...
NCT ID: NCT03081858
State: Multi-State Trial Investigator/Sponsoring Organization: TesoRx Pharma, LLC
Study of Atezolizumab Plus PGV001, a Multipeptide Personalized Neoantigen Vaccine, in Patients With ...
NCT ID: NCT03359239
State: New York Investigator/Sponsoring Organization: Matthew Galsky
An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothe...
NCT ID: NCT04045613
State: Multi-State Trial Investigator/Sponsoring Organization: Basilea Pharmaceutica
Study of Neoadjuvant sEphB4-HSA in Patients With Stage ll Bladder Cancer
NCT ID: NCT02767921
State: California Investigator/Sponsoring Organization: University of Southern California
Evaluating the Efficacy and Safety of UGN-101 (Mitomycin Gel) for Instillation on Ablation of Upper ...
NCT ID: NCT04006691
State: Multi-State Trial Investigator/Sponsoring Organization: UroGen Pharma Ltd.
Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-6...
NCT ID: NCT03473743
State: Multi-State Trial Investigator/Sponsoring Organization: Janssen Research & Development, LLC
Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination Wi...
NCT ID: NCT02619253
State: Multi-State Trial Investigator/Sponsoring Organization: Roberto Pili
Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Pa...
NCT ID: NCT02812420
State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center
Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Can...
NCT ID: NCT03236935
State: Texas Investigator/Sponsoring Organization: Jorge G. Darcourt
Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi...
NCT ID: NCT02496208
State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI)
Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-...
NCT ID: NCT03523572
State: Multi-State Trial Investigator/Sponsoring Organization: Daiichi Sankyo, Inc.
Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metasta...
NCT ID: NCT03650348
State: Multi-State Trial Investigator/Sponsoring Organization: Pieris Pharmaceuticals, Inc.
A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or M...
NCT ID: NCT03330561
State: Multi-State Trial Investigator/Sponsoring Organization: Pieris Pharmaceuticals, Inc.
Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Po...
NCT ID: NCT02989064
State: Multi-State Trial Investigator/Sponsoring Organization: Adaptimmune
Study of Intra-tumoral Injections in Metastatic Urological Cancers
NCT ID: NCT03071328
State: North Carolina Investigator/Sponsoring Organization: Duke University
An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects W...
NCT ID: NCT03474107
State: Multi-State Trial Investigator/Sponsoring Organization: Astellas Pharma Global Development, Inc.
Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell%2FNeuroendocrine Cancers of U...
NCT ID: NCT03582475
State: California Investigator/Sponsoring Organization: Jonsson Comprehensive Cancer Center
Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma ...
NCT ID: NCT02632409
State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb
MK3475 + Docetaxel or Gemcitabine in Platinum Pre-treated Urothelial Cancer
NCT ID: NCT02437370
State: California Investigator/Sponsoring Organization: University of California, Davis
STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06939...
NCT ID: NCT03854227
State: Multi-State Trial Investigator/Sponsoring Organization: Pfizer
NKTR-214 in Combination With Anti-PD-1 (Pembrolizumab) or Anti-PD-L1 (Atezolizumab) in Patients With...
NCT ID: NCT03138889
State: Multi-State Trial Investigator/Sponsoring Organization: Nektar Therapeutics
SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacoki...
NCT ID: NCT03992131
State: Multi-State Trial Investigator/Sponsoring Organization: Clovis Oncology, Inc.
Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Block...
NCT ID: NCT03639714
State: Multi-State Trial Investigator/Sponsoring Organization: Gritstone Oncology, Inc.
Study of Ibrutinib Combination Therapy in Selected Advanced Urothelial or Bladder Cancer Tumors
NCT ID: NCT02599324
State: Multi-State Trial Investigator/Sponsoring Organization: Pharmacyclics LLC.
Study of ADXS NEO Expressing Personalized Tumor Antigens, Alone and in Combination With Pembrolizuma...
NCT ID: NCT03265080
State: Multi-State Trial Investigator/Sponsoring Organization: Advaxis, Inc.
A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Ther...
NCT ID: NCT03288545
State: Multi-State Trial Investigator/Sponsoring Organization: Astellas Pharma Global Development, Inc.
Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid ...
NCT ID: NCT03076372
State: Multi-State Trial Investigator/Sponsoring Organization: Merrimack Pharmaceuticals
Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º...
NCT ID: NCT03132922
State: Multi-State Trial Investigator/Sponsoring Organization: Adaptimmune
Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuva...
NCT ID: NCT03633110
State: Multi-State Trial Investigator/Sponsoring Organization: Genocea Biosciences, Inc.
Study of INBRX-105 in Patients With Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodg...
NCT ID: NCT03809624
State: Multi-State Trial Investigator/Sponsoring Organization: Inhibrx, Inc.
Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid...
NCT ID: NCT03517488
State: Multi-State Trial Investigator/Sponsoring Organization: Xencor, Inc.
A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combi...
NCT ID: NCT02983045
State: Multi-State Trial Investigator/Sponsoring Organization: Nektar Therapeutics
Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid...
NCT ID: NCT03752398
State: Multi-State Trial Investigator/Sponsoring Organization: Xencor, Inc.
Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
NCT ID: NCT03409458
State: Multi-State Trial Investigator/Sponsoring Organization: Phosplatin Therapeutics
Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors
NCT ID: NCT04044859
State: Multi-State Trial Investigator/Sponsoring Organization: Adaptimmune
Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With...
NCT ID: NCT03894618
State: Multi-State Trial Investigator/Sponsoring Organization: Shattuck Labs, Inc.
Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pemb...
NCT ID: NCT03849469
State: Multi-State Trial Investigator/Sponsoring Organization: Xencor, Inc.
The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to ...
NCT ID: NCT03758781
State: Florida Investigator/Sponsoring Organization: H. Lee Moffitt Cancer Center and Research Institute
Study of TPST-1120 as a Single Agent or in Combination With Systemic Anti-Cancer Therapies in Subjec...
NCT ID: NCT03829436
State: Multi-State Trial Investigator/Sponsoring Organization: Tempest Therapeutics
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced ...
NCT ID: NCT03841110
State: Multi-State Trial Investigator/Sponsoring Organization: Fate Therapeutics
Study of INCAGN02390 in Participants With Select Advanced Malignancies
NCT ID: NCT03652077
State: Multi-State Trial Investigator/Sponsoring Organization: Incyte Corporation
Study of INCAGN02385 in Participants With Select Advanced Malignancies
NCT ID: NCT03538028
State: Multi-State Trial Investigator/Sponsoring Organization: Incyte Biosciences International Sàrl
Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers
NCT ID: NCT03212404
State: Multi-State Trial Investigator/Sponsoring Organization: Checkpoint Therapeutics, Inc.
Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atez...
NCT ID: NCT03289962
State: Multi-State Trial Investigator/Sponsoring Organization: Genentech, Inc.
Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With...
NCT ID: NCT03023319
State: Ohio Investigator/Sponsoring Organization: Nagla Karim
Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinati...
NCT ID: NCT03872947
State: Multi-State Trial Investigator/Sponsoring Organization: Toray Industries, Inc
Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With ...
NCT ID: NCT03454451
State: Multi-State Trial Investigator/Sponsoring Organization: Corvus Pharmaceuticals, Inc.
A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participant...
NCT ID: NCT03629756
State: Multi-State Trial Investigator/Sponsoring Organization: Arcus Biosciences, Inc.
Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incu...
NCT ID: NCT02655822
State: Multi-State Trial Investigator/Sponsoring Organization: Corvus Pharmaceuticals, Inc.
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab...
NCT ID: NCT03621982
State: Multi-State Trial Investigator/Sponsoring Organization: ADC Therapeutics S.A.
A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy...
NCT ID: NCT03628677
State: Multi-State Trial Investigator/Sponsoring Organization: Arcus Biosciences, Inc.
Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malignancies
NCT ID: NCT02897375
State: Georgia Investigator/Sponsoring Organization: Emory University
Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Maligna...
NCT ID: NCT03590054
State: California Investigator/Sponsoring Organization: Rahul Aggarwal
Phase Ib Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patie...
NCT ID: NCT02869217
State: Ontario Investigator/Sponsoring Organization: University Health Network, Toronto
Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
NCT ID: NCT03329950
State: Multi-State Trial Investigator/Sponsoring Organization: Celldex Therapeutics
Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Pati...
NCT ID: NCT01552434
State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center
Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With ...
NCT ID: NCT03637803
State: Texas Investigator/Sponsoring Organization: 4D pharma plc
Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects Wit...
NCT ID: NCT03170960
State: Multi-State Trial Investigator/Sponsoring Organization: Exelixis
Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
NCT ID: NCT03767348
State: Multi-State Trial Investigator/Sponsoring Organization: Replimune Inc.
Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combi...
NCT ID: NCT03678883
State: Multi-State Trial Investigator/Sponsoring Organization: Actuate Therapeutics Inc.
Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor R...
NCT ID: NCT03602079
State: Multi-State Trial Investigator/Sponsoring Organization: Klus Pharma Inc.
Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Recep...
NCT ID: NCT02643303
State: Multi-State Trial Investigator/Sponsoring Organization: Ludwig Institute for Cancer Research
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor IN...
NCT ID: NCT02903914
State: Multi-State Trial Investigator/Sponsoring Organization: Incyte Corporation
Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in P...
NCT ID: NCT03250832
State: Multi-State Trial Investigator/Sponsoring Organization: Tesaro, Inc.
Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in C...
NCT ID: NCT03682068
State: Multi-State Trial Investigator/Sponsoring Organization: AstraZeneca
Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studie...
NCT ID: NCT03815643
State: Multi-State Trial Investigator/Sponsoring Organization: EMD Serono Research & Development Institute, Inc.
Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
NCT ID: NCT03674567
State: Multi-State Trial Investigator/Sponsoring Organization: RAPT Therapeutics, Inc.
Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P...
NCT ID: NCT03970382
State: Multi-State Trial Investigator/Sponsoring Organization: PACT Pharma, Inc.
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or...
NCT ID: NCT03884556
State: Multi-State Trial Investigator/Sponsoring Organization: Tizona Therapeutics, Inc
udy to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK332659...
NCT ID: NCT02783300
State: Multi-State Trial Investigator/Sponsoring Organization: GlaxoSmithKline
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination Wit...
NCT ID: NCT03126110
State: Multi-State Trial Investigator/Sponsoring Organization: Incyte Biosciences International Sàrl
A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of...
NCT ID: NCT03989115
State: Multi-State Trial Investigator/Sponsoring Organization: Revolution Medicines, Inc.
Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ...
NCT ID: NCT03739931
State: Multi-State Trial Investigator/Sponsoring Organization: ModernaTX, Inc.
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus...
NCT ID: NCT03898180
State: Multi-State Trial Investigator/Sponsoring Organization: Merck Sharp & Dohme Corp.
Window of Opportunity Platform Study to Define Immunogenomic Changes With Pembrolizumab Alone and in...
NCT ID: NCT03978624
State: North Carolina Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
NCT ID: NCT03933826
State: Multi-State Trial Investigator/Sponsoring Organization: University of Washington
Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach
NCT ID: NCT00848289
State: Multi-State Trial Investigator/Sponsoring Organization: M.D. Anderson Cancer Center
Familial and Atypical Urothelial Cancer Registry
NCT ID: NCT00902590
State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center
Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic...
NCT ID: NCT03219333
State: Multi-State Trial Investigator/Sponsoring Organization: Astellas Pharma Global Development, Inc.
Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bladder Cance...
NCT ID: NCT03609216
State: Multi-State Trial Investigator/Sponsoring Organization: Alliance for Clinical Trials in Oncology
PORCH: A Registry of Prospective Outcomes of Radical Cystectomy With or Without Chemotherapy
NCT ID: NCT01776138
State: North Carolina Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center
Imaging of Bladder Cancer Using Clinical 3 Tesla MRI and EX-VIVO Ultra-High-Field MRI.
NCT ID: NCT00938145
State: Ohio Investigator/Sponsoring Organization: Ohio State University Comprehensive Cancer Center
Pilot Testing for Post-Cystectomy mHealth Tool to Improve Perioperative Care
NCT ID: NCT03862105
State: North Carolina Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center
Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry Optional Sub-Study I: ...
NCT ID: NCT02852252
State: Pennsylvania Investigator/Sponsoring Organization: University of Pennsylvania
Prevention of Parastomal Hernia Following Radical Cystectomy and Ileal Conduit Using Biologic Mesh: ...
NCT ID: NCT02439060
State: California Investigator/Sponsoring Organization: University of Southern California
Study of Durvalumab With Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer
NCT ID: NCT03912818
State: California Investigator/Sponsoring Organization: Stanford University
Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Perfo...
NCT ID: NCT01224665
State: Multi-State Trial Investigator/Sponsoring Organization: Southwest Oncology Group
Study of Adjuvant 3D-Conformal Radiotherapy in High Risk Bladder Cancer
NCT ID: NCT01954173
State: Georgia Investigator/Sponsoring Organization: Emory University
Measuring Surgical Recovery After Radical Cystectomy
NCT ID: NCT03193970
State: Multi-State Trial Investigator/Sponsoring Organization: M.D. Anderson Cancer Center
Evaluation for NCI Surgery Branch Clinical Research Protocols
NCT ID: NCT00001823
State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI)
Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Ci...
NCT ID: NCT03520491
State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center
Study of Motility Contrast Tomography for Predicting Therapeutic Response
NCT ID: NCT03739177
State: Indiana Investigator/Sponsoring Organization: Animated Dynamics, Inc.
Assessment of Reliability of Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladd...
NCT ID: NCT02968732
State: Pennsylvania Investigator/Sponsoring Organization: Fox Chase Cancer Center
Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
NCT ID: NCT03757949
State: Multi-State Trial Investigator/Sponsoring Organization: Southwest Oncology Group
Radiation Therapy and Anti-PD-L1 Checkpoint Inhibitor (Durvalumab) With or Without Anti-CTLA-4 Inhib...
NCT ID: NCT03601455
State: California Investigator/Sponsoring Organization: Jonsson Comprehensive Cancer Center
Intra-corporal vs Extra-corporal Urinary Diversion After Robot Assisted Radical Cystectomy
NCT ID: NCT03469362
State: Florida Investigator/Sponsoring Organization: University of Miami
Intraoperative Intravesical Instillation of Mitomycin C During Nephroureterectomy for Urothelial Car...
NCT ID: NCT03658304
State: Florida Investigator/Sponsoring Organization: University of Florida
Neutron Radiotherapy With Concurrent Checkpoint Inhibitor Immunotherapy (Pembrolizumab) in Patients ...
NCT ID: NCT03486197
State: Washington Investigator/Sponsoring Organization: University of Washington
A Phase II Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 Inhibitor in C...
NCT ID: NCT03737123
State: Multi-State Trial Investigator/Sponsoring Organization: Nabil Adra
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial C...
NCT ID: NCT03534804
State: Utah Investigator/Sponsoring Organization: University of Utah
sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-7435) for Metastatic Urothelial C...
NCT ID: NCT02717156
State: Multi-State Trial Investigator/Sponsoring Organization: University of Southern California
Defining the Genomic and Histologic Landscape of Primary and Metastatic Tumors With Divergent Kineti...
NCT ID: NCT03291028
State: Pennsylvania Investigator/Sponsoring Organization: Fox Chase Cancer Center
Study of Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refractory Urothelial Carcinoma
NCT ID: NCT02581982
State: North Carolina Investigator/Sponsoring Organization: Wake Forest University Health Sciences
GU-114: Overcoming Checkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer
NCT ID: NCT03179943
State: Multi-State Trial Investigator/Sponsoring Organization: Fox Chase Cancer Center
Study of Check Point Inhibitor, Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refractory ...
NCT ID: NCT02901548
State: Multi-State Trial Investigator/Sponsoring Organization: H. Lee Moffitt Cancer Center and Research Institute
Phase II Trial of Concurrent Nivolumab in Urothelial Bladder Cancer With Radiation Therapy in Locali...
NCT ID: NCT03421652
State: Michigan Investigator/Sponsoring Organization: Barbara Ann Karmanos Cancer Institute
Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blocka...
NCT ID: NCT03557918
State: Multi-State Trial Investigator/Sponsoring Organization: Matthew Galsky
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER)
NCT ID: NCT02710734
State: Multi-State Trial Investigator/Sponsoring Organization: Fox Chase Cancer Center
Study of Avelumab in Combination With Bladder-Directed Radiation in Cisplatin-Ineligible Patients Wi...
NCT ID: NCT03747419
State: Multi-State Trial Investigator/Sponsoring Organization: Dana-Farber Cancer Institute
Prevalence of PD-L1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metasta...
NCT ID: NCT03788746
State: Multi-State Trial Investigator/Sponsoring Organization: AstraZeneca
Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial ...
NCT ID: NCT03272217
State: Multi-State Trial Investigator/Sponsoring Organization: Arjun Balar, MD
Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects With Non-metastatic Transitional Cell Carcino...
NCT ID: NCT02451423
State: California Investigator/Sponsoring Organization: University of California, San Francisco
Study of Sitravatinib in Combination With Nivolumab in Patients With Advanced or Metastatic Urotheli...
NCT ID: NCT03606174
State: Multi-State Trial Investigator/Sponsoring Organization: Mirati Therapeutics Inc.
Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) With Pembrolizumab, in Subjects Who Have...
NCT ID: NCT03935347
State: New York Investigator/Sponsoring Organization: Roswell Park Cancer Institute
Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination With IPI-549 Comp...
NCT ID: NCT03980041
State: Multi-State Trial Investigator/Sponsoring Organization: Infinity Pharmaceuticals, Inc.
Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL-7 (CYT107) in Patients With Locally Adva...
NCT ID: NCT03513952
State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI)
Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD...
NCT ID: NCT03547973
State: Multi-State Trial Investigator/Sponsoring Organization: Immunomedics, Inc.
Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma With DNA-Repai...
NCT ID: NCT03375307
State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI)
Combination Therapy With Pemetrexed and Avelumab in Previously Treated Patients With MTAP-Deficient ...
NCT ID: NCT03744793
State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center
Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Metastatic or...
NCT ID: NCT02872714
State: Multi-State Trial Investigator/Sponsoring Organization: Incyte Corporation
Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
NCT ID: NCT02567409
State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI)
Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy
NCT ID: NCT01050504
State: Washington Investigator/Sponsoring Organization: University of Washington
Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in P...
NCT ID: NCT03047213
State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI)
Atezolizumab in Combination With Gemcitabine and Cisplatin As First-Line Treatment in Metastatic Uro...
NCT ID: NCT03093922
State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT ID: NCT03452774
State: New York Investigator/Sponsoring Organization: Massive Bio, Inc.
Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tum...
NCT ID: NCT03682289
State: California Investigator/Sponsoring Organization: Rahul Aggarwal
Study for the Production of a Patient-Specific Neoantigen Cancer Vaccine and Screening Study for a S...
NCT ID: NCT03794128
State: Multi-State Trial Investigator/Sponsoring Organization: Gritstone Oncology, Inc.
The PIONEER Initiative: Precision Insights On N-of-1 Effectiveness Research. Tissue Ownership by the...
NCT ID: NCT03896958
State: Georgia Investigator/Sponsoring Organization: SpeciCare
Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in S...
NCT ID: NCT02795156
State: Multi-State Trial Investigator/Sponsoring Organization: SCRI Development Innovations, LLC
Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
NCT ID: NCT03866382
State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI)
QUILT-3.055: Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients Who Ha...
NCT ID: NCT03228667
State: Multi-State Trial Investigator/Sponsoring Organization: Altor BioScience
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
NCT ID: NCT02834013
State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI)
Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immune ...
NCT ID: NCT02978118
State: North Carolina Investigator/Sponsoring Organization: Duke University
Study of Bempegaldesleukin (NKTR-214) in Combination With Nivolumab in Cisplatin Ineligible, Locally...
NCT ID: NCT03785925
State: Multi-State Trial Investigator/Sponsoring Organization: Nektar Therapeutics
Study of Regorafenib for Advanced Urothelial Cancer Following Prior Chemotherapy
NCT ID: NCT02459119
State: Multi-State Trial Investigator/Sponsoring Organization: University of Alabama at Birmingham
LCI-GU-URO-CRI-001: Study of Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial...
NCT ID: NCT02612194
State: North Carolina Investigator/Sponsoring Organization: Earle Burgess
Intensive Preoperative Ostomy Education for the Radical Cystectomy Patient
NCT ID: NCT03462667
State: Kansas Investigator/Sponsoring Organization: University of Kansas Medical Center
Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard ...
NCT ID: NCT03036098
State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb
Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Admin...
NCT ID: NCT01968109
State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb
Trial of Preventive Mesh Placement at the Time of Radical Cystectomy to Reduce the Chances of Develo...
NCT ID: NCT02908061
State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center
Study of Gemcitabine and Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystec...
NCT ID: NCT02690558
State: Multi-State Trial Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center
Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BC...
NCT ID: NCT03022825
State: Multi-State Trial Investigator/Sponsoring Organization: Altor BioScience
Study of BC-819 in Patients With Non-Muscle Invasive Bladder Cancer Whose Disease is Unresponsive to...
NCT ID: NCT03719300
State: Multi-State Trial Investigator/Sponsoring Organization: Anchiano Therapeutics Israel Ltd.
Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects With High Risk Non-muscle Invas...
NCT ID: NCT02625961
State: Multi-State Trial Investigator/Sponsoring Organization: Merck Sharp & Dohme Corp.
Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as...
NCT ID: NCT02621151
State: Multi-State Trial Investigator/Sponsoring Organization: NYU Langone Health
Trial of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cispl...
NCT ID: NCT03451331
State: Multi-State Trial Investigator/Sponsoring Organization: Matthew Galsky
Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With ...
NCT ID: NCT02516241
State: Multi-State Trial Investigator/Sponsoring Organization: AstraZeneca
Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advance...
NCT ID: NCT03390504
State: Multi-State Trial Investigator/Sponsoring Organization: Janssen Research & Development, LLC
Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer
NCT ID: NCT02122172
State: Multi-State Trial Investigator/Sponsoring Organization: University of Chicago
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene A...
NCT ID: NCT03448718
State: Multi-State Trial Investigator/Sponsoring Organization: Matthew Galsky
Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditionin...
NCT ID: NCT02111850
State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI)
Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX -2011 and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhib...
NCT ID: NCT03989362
State: Multi-State Trial Investigator/Sponsoring Organization: Jounce Therapeutics, Inc.
Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Ur...
NCT ID: NCT02475213
State: Multi-State Trial Investigator/Sponsoring Organization: MacroGenics
Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
NCT ID: NCT03679767
State: Multi-State Trial Investigator/Sponsoring Organization: Incyte Corporation
Trial With Expansion Cohorts to Evaluate Safety of GEN1029 in Patients With Malignant Solid Tumors
NCT ID: NCT03576131
State: Multi-State Trial Investigator/Sponsoring Organization: Genmab
Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)
NCT ID: NCT02393248
State: Multi-State Trial Investigator/Sponsoring Organization: Incyte Corporation
Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics...
NCT ID: NCT03666273
State: Multi-State Trial Investigator/Sponsoring Organization: Bayer
Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent...
NCT ID: NCT03821935
State: Multi-State Trial Investigator/Sponsoring Organization: AbbVie
Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermedi...
NCT ID: NCT03914794
State: Maryland Investigator/Sponsoring Organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of QUILT-3.032 (CA ALT-803-01-16): A Multicenter Clinical Trial of Intravesical Bacillus Calme...
NCT ID: NCT04142359
State: Multi-State Trial Investigator/Sponsoring Organization: Altor BioScience
Bacillus Calmette-Guérin (BCG) and Intravesical Gemcitabine for Patients With BCG-Relapsing High-Gra...
NCT ID: NCT04179162
State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center
Trial Evaluating the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid ...
NCT ID: NCT04157985
State: Pennsylvania Investigator/Sponsoring Organization: Antoinette J Wozniak